Table 2. Disease status at trial entry and previous treatments.
| Previous treatment details | |
|---|---|
| Prior lines of chemotherapy | |
| Median (range) | 2 (1–5) |
| 1 | 18 |
| 2 | 12 |
| 3⩾ | 11 |
| Prior high-dose chemotherapy | |
| Yes | 6 |
| No | 35 |
| Prior radiotherapy | |
| Yes | 18 |
| No | 23 |
| Prior rituximab | |
| Yes | 7 |
| No | 34 |
| Disease status | |
| Primary progressivea | 8 patients |
| 1st relapse | 9 patients |
| 2nd relapse | 11 patients |
| 3rd and subsequent relapse | 13 patients |
| Remission duration b | |
| < 1 year | 29 patients |
| > 1 year | 12 patients |
| Chemosensitivec | 22 |
| Chemoresistantd | 19 |
a
Disease progression during or within 90 days of completion of induction treatment.
b
Disease-free interval from end of last treatment till relapse.
c
Response to prior chemotherapy lasting greater than 90 days from completion of treatment.
d
Disease progression during or within 90 days of completion of last chemotherapy.